Harmoni Gallegos
Family · Groesbeck, TXNPI 1801441365
Payments from drug & device makers
Across 97 payments — averaging $17.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$309
- Lundbeck LLC$270
- Otsuka America Pharmaceutical, Inc.$136
- Novo Nordisk$132
- Amgen$130
- Bayer$114
- plus $647 from 14 others
What the payments were for
- Food & beverage$1,735100%
- Education$50%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 15 | $309 |
| Lundbeck LLC | 19 | $270 |
| Otsuka America Pharmaceutical, Inc. | 6 | $136 |
| Novo Nordisk | 7 | $132 |
| Amgen | 8 | $130 |
| Bayer | 7 | $114 |
| Merck | 5 | $86 |
| GSK | 5 | $86 |
| Sumitomo Pharma America, Inc. | 1 | $71 |
| Lilly USA, LLC | 4 | $68 |
| Exact Sciences | 3 | $50 |
| Phathom Pharmaceuticals, Inc. | 5 | $50 |
| Axsome Therapeutics, Inc. | 2 | $44 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $43 |
| AbbVie | 2 | $38 |
| Organon | 1 | $36 |
| Pfizer | 1 | $25 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $21 |
| Dexcom, Inc. | 1 | $16 |
| Electromed, Inc. | 1 | $14 |
How this compares
$1,739 in reported general payments places this provider in the 75th percentile of 15,456 family providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 36 | $49,684 |
| JardianceEmpagliflozin | 29 | $37,006 |
| EliquisApixaban | 25 | $27,453 |
| FarxigaDapagliflozin Propanediol | 23 | $26,492 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 29 | $19,003 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 18 | $13,176 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 11 | $10,183 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 29 | $6,495 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 99 | $2,593 |
| Gabapentin | 96 | $1,960 |
| Rosuvastatin Calcium | 110 | $1,907 |
| SynthroidLevothyroxine Sodium | 14 | $1,609 |
| Atorvastatin Calcium | 216 | $1,447 |
| Losartan Potassium | 107 | $1,368 |
| Omeprazole | 87 | $1,059 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $132 | $49,68436 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $309 | $36,67534 claims |
| PfizerEliquis | $25 | $27,45325 claims |
| GSKTrelegy Ellipta | $86 | $19,00329 claims |
| MerckJanumet Xr | $86 | $13,17618 claims |
| AbbVieSynthroid | $38 | $1,60914 claims |
| Lilly USA, LLCOlanzapine | $68 | $28414 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 15,456 family providers in Texas.
Other family in Groesbeck
- Lashonda CraneHouston$3.4M
- David WeirDallas$959K
- Luba YammineHouston$479K
- Robin BeachHouston$428K
- Nirupama JeromeAustin$418K
- April LopezMcAllen$417K
- Linda MercadoHouston$211K
- Sarah AguilarHouston$199K
- Sie ThomasDallas$197K
- Anna CastroSan Antonio$184K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.